Oral Contraceptive Options for PCOS (Other Than Tri-Lo-Mili)
For women with PCOS requiring contraception, combined oral contraceptives containing ethinyl estradiol (30-35 μg) with levonorgestrel or norgestimate are appropriate first-line options, with ethinyl estradiol/cyproterone acetate (EE/CPA) being more effective for severe hyperandrogenism but reserved for second-line due to higher VTE risk. 1, 2
First-Line COC Options
Monophasic pills with 30-35 μg ethinyl estradiol combined with:
- Levonorgestrel (second-generation progestin)
- Norgestimate (third-generation progestin)
These formulations provide effective cycle regulation, reduce hyperandrogenism, and have well-established safety profiles 1, 3. The evidence shows no clear superiority of one formulation over another for standard PCOS management, making cost and insurance coverage reasonable deciding factors 1.
Second-Line Options for Severe Hyperandrogenism
When hirsutism, acne, or androgenic symptoms are particularly severe and unresponsive to first-line agents:
Antiandrogen-containing COCs:
- Ethinyl estradiol/cyproterone acetate (EE/CPA): Most effective for reducing hirsutism and biochemical hyperandrogenism (testosterone reduction MD 0.38 nmol/L), also reduces BMI more effectively than conventional COCs 2
- Ethinyl estradiol/drospirenone: Fourth-generation progestin with antiandrogenic properties, results in lower BMI and testosterone compared to third-generation agents 2, 4
- Ethinyl estradiol/dienogest: Another antiandrogen option with favorable metabolic profile 4
Critical caveat: EE/CPA carries higher venous thromboembolism risk than other COCs in the general population, limiting its use to cases where benefits clearly outweigh risks 2, 5.
Alternative Hormonal Contraceptive Routes
Contraceptive vaginal ring (NuvaRing): Releases 15 μg ethinyl estradiol and 120 μg etonogestrel daily. Offers comparable efficacy and benefits to COCs with simpler dosing regimen (monthly insertion) 1. Particularly useful for adolescents with adherence challenges.
Transdermal contraceptive patch: Similar efficacy to oral formulations, may improve compliance 1.
Special Considerations
For adolescents with PCOS: Start with low-dose COCs (30-35 μg ethinyl estradiol) in monophasic formulations. Extended or continuous cycling may be particularly beneficial for those with severe dysmenorrhea or desire for amenorrhea 1, 6.
When contraception is not required but cycle regulation needed: Consider cyclic progestin (micronized progesterone 200 mg or medroxyprogesterone acetate 10 mg for 12-14 days every 28 days) for endometrial protection 7.
Metabolic risk factors present: Before prescribing any COC, document baseline cardiovascular risk factors including age, smoking status, BMI, glucose tolerance, blood pressure, lipids, and personal/family history of VTE 8, 9. Women with multiple metabolic risk factors or morbid obesity with severe insulin resistance may benefit from metformin as adjunctive therapy rather than relying solely on COCs 9, 10.
Practical Implementation
Dosing strategy: Start with monophasic pills providing monthly bleeding, then adjust to extended cycles (84/7 or continuous) if indicated for symptom control or patient preference 1. Extended cycles optimize ovarian suppression and may improve contraceptive effectiveness, especially important given adolescents' higher rates of missed pills 1.
Monitoring: Reassess cardiovascular risk factors at follow-up visits, particularly if baseline risk factors were present. Schedule initial follow-up at 1-3 months to address adverse effects and adherence 3.
Common pitfall: Avoid using polycystic ovarian morphology on ultrasound or anti-Müllerian hormone levels for PCOS diagnosis in adolescents, as these are not appropriate diagnostic criteria in this age group 6.